Commercial ApprovalElfabrio remains favorable with commercial approval across 23 territories globally for the treatment of Fabry disease.
Financial PositionThe company has $34.7M in cash and short-term bank deposits, expected to be sufficient to fund operations to cash flow breakeven.
Market OpportunityProtalix management indicated that the total Fabry disease market opportunity may raise significantly by 2030, with potential substantial royalty streams from Elfabrio.